A non-interventional prospective study of 1-st line treatment approaches in OVArian cancer patients with HRD+ status in Russian Federation - OVARD

Study identifier:D133FR00195

ClinicalTrials.gov identifier:NCT05918042

EudraCT identifier:N/A

CTIS identifier:N/A

Recruiting

Official Title

Multicentre, non-interventional, observational, prospective study to evaluate 1-st line treatment approaches in HRD+ ovarian cancer patients in Russian Federation

Medical condition

ovarian cancer

Phase

N/A

Healthy volunteers

No

Study drug

-

Sex

Female

Estimated Enrollment

400

Study type

Observational

Age

18 Years - n/a

Date

Study Start Date: 21 Jun 2023
Estimated Primary Completion Date: 31 Dec 2024
Estimated Study Completion Date: 31 Dec 2024

Study design

Allocation: N/A
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -

Verification:

Verified 01 Feb 2024 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria